{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-26-000025","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2026-07-30T10:15:42+00:00","discovered_at":"2026-07-30T10:20:00.328281+00:00","generated_at":"2026-07-30T10:20:20.172635+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amneal Q2 net revenue $796M (+10% YoY); GAAP EPS $0.18; raises FY 2026 guidance","bullets":["Net revenue $796M (+10% YoY); GAAP net income $58M, diluted EPS $0.18 (vs $0.07 YoY).","Adjusted EBITDA $206M (+12% YoY); adjusted diluted EPS $0.30 (+20% YoY).","Specialty revenue +17% driven by CREXONT, BREKIYA, UNITHROID; Affordable Medicines +13% on complex portfolio.","Raising full-year 2026 guidance for second time this year; debt repricing in July reduces interest cost.","Pending Kashiv transaction to establish biosimilars as new growth vertical."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-26-000025","json":"https://secwatch.observer/filing/0001723128-26-000025.json","markdown":"https://secwatch.observer/filing/0001723128-26-000025.md","text":"https://secwatch.observer/filing/0001723128-26-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/0001723128-26-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312826000025/amrx-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T10:20:20.172635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}